| | | | | | | | |
| Name | | Jurisdiction of Incorporation |
| Ab Initio Biotherapeutics, Inc. | | Delaware |
| Adjacent Acquisition Co., LLC | | Delaware |
| Glycomed Incorporated | | California |
| Allergan Ligand Retinoid Therapeutics, Inc. | | Delaware |
| Ligand Pharmaceuticals International, Inc. | | Delaware |
| Ligand Biopharmaceuticals Incorporated | | Delaware |
| Ligand JVR, Inc. | | Delaware |
| Ligand Pharmaceuticals UK Limited | | United Kingdom |
| Ligand Pharmaceuticals (Canada) Incorporated | | Canada |
| Seragen Incorporated | | Delaware |
| Seragen Technology, Inc. | | Delaware |
| Pharmacopeia, LLC | | Delaware |
| Metabasis Therapeutics, Inc. | | Delaware |
| Neurogen Corporation | | Delaware |
| CyDex Pharmaceuticals, Inc. | | Delaware |
| Open Monoclonal Technology, Inc. | | Delaware |
| OMT I, Inc. | | Delaware |
| OMT II, Inc. | | Delaware |
| Crystal Bioscience, Inc. | | California |
| Vernalis plc | | England and Wales |
| Vernalis (R&D) Limited | | England and Wales |
| Vernalis Group Limited | | England and Wales |
| Vernalis Therapeutics Inc. | | Delaware |
| Vernalis (Canada) Inc. | | Canada |
| Vernalis (Canada II) Inc. | | Canada |
| Vernalis Development Limited | | England and Wales |
| Vernalis Research Limited | | England and Wales |
| Cita NeuroPharmaceuticals Inc. | | Canada |